Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Mahmoud Ellithy"'
Autor:
Noha Salah El Baghdady, Lamia Elwakeel, Mahmoud Ellithy, Nawal Hussein, Sara Shahin, Abdel Rahman El Naggar
Publikováno v:
Archives of Pharmaceutical Sciences Ain Shams University, Vol 4, Iss 2, Pp 224-236 (2020)
Objectives: Sorafenib is the standard first-line treatment for HCC. No sufficient data exists regarding its efficacy in the Egyptian population being a costly medication that is not endorsed by insurance and hence is not used in most institutions. Th
Externí odkaz:
https://doaj.org/article/0ce21cff2cdc49c4b346260ff993f749
Publikováno v:
Research in Oncology, Vol 15, Iss 2, Pp 46-52 (2019)
Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. Aim: To compare betw
Externí odkaz:
https://doaj.org/article/2868ee2b07f64c288e8b93d36db2d0d6
Publikováno v:
Research in Oncology, Vol 14, Iss 2, Pp 53-58 (2018)
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a common toxicity with no proven agent beneficial for prevention. The potentiality of Nerve Growth Factor (NGF) as a protective agent for PIPN was suggested by several studies. Aim: This
Externí odkaz:
https://doaj.org/article/9569542e70b64d768a3b417ff6ab5d3e
Publikováno v:
Research in Oncology, Vol 14, Iss 1, Pp 6-11 (2018)
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor. The outcome of treatment of EgyptianMPM patients is not satisfactory and its cost-effectiveness is questionable.Aim: The study aimed to test the treatment outcome and cost-effec
Externí odkaz:
https://doaj.org/article/3a88593439f6459394a92a50955a49b8
Autor:
Omar Abdel-Rahman, Manal Abdelwahab, Mohammed Shaker, Sherif Abdelwahab, Mohammed Elbassiony, Mahmoud Ellithy
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 26, Iss 1, Pp 9-13 (2014)
Background: According to the results of a number of phase 3 randomized studies, sorafenib is the only approved systemic therapy for advanced HCC; however the issue of high economic cost remains challenging; thus we have conducted this retrospective a
Externí odkaz:
https://doaj.org/article/518d9e3893004aa38877b2a6bbe7cd91
Publikováno v:
Research in Oncology, Vol 15, Iss 2, Pp 46-52 (2019)
Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. Aim: To compare betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6399807d51e890238593d6665f6e52e9
https://doi.org/10.21608/resoncol.2019.12516.1078
https://doi.org/10.21608/resoncol.2019.12516.1078
Publikováno v:
QJM: An International Journal of Medicine. 113
Background Lung cancer has been the most common cancer overall for several decades. According to the last data of GLOBOCAN series of the International Agency for Research on Cancer there were estimated 1.8 million new cases in 2012 of which 1.2 milli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::464ce3e37a97d1e60e97c9e53b4e84c9
https://doi.org/10.1093/qjmed/hcaa057.008
https://doi.org/10.1093/qjmed/hcaa057.008
Publikováno v:
Research in Oncology, Vol 14, Iss 2, Pp 53-58 (2018)
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a common toxicity with no proven agent beneficial for prevention. The potentiality of Nerve Growth Factor (NGF) as a protective agent for PIPN was suggested by several studies. Aim: This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c23b70e9f97f182dd8f71da1e3d3d2b3
https://doi.org/10.21608/resoncol.2018.3375.1055
https://doi.org/10.21608/resoncol.2018.3375.1055
Publikováno v:
Journal of Cancer Therapy. :839-849
Objectives: In this study molecular/genomic characteristics were done on new tissue biopsies taken from Egyptian patients with refractory metastatic solid tumors aiming for two end points: To figure out a personalized treatment and to find the percen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ac1629e123d2042152034b56a97206c
https://doi.org/10.4236/jct.2018.911069
https://doi.org/10.4236/jct.2018.911069
Autor:
Khalil El Habak, Ahmed Reda, Mahmoud Ellithy, Ahmed Sobhy, Randa M. Mostafa, Wesam M. El-Bakly, Amr Marzouk, Omar Wagdy, Mahmoud A. Ali, Ayman El-Sayed Shafei, Omar Aboelenin
Publikováno v:
Biomedicine & Pharmacotherapy. 95:1209-1218
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with subsequent therapeutic failure and adverse effects. DOX- induced cardiotoxicity is a major problem that necessitates the presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a2d52d294729201e2c8cf26e82eb806
https://doi.org/10.1016/j.biopha.2017.09.059
https://doi.org/10.1016/j.biopha.2017.09.059